Arch Biopartners Inc. (ARCH.V)
Arch Biopartners Inc., engages in the development of novel drugs for acute kidney injury and organ damage in Canada.
0.81-0.05%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-53.7%
The outlook
Arch Biopartners Inc. currently reads as neutral based on mixed vs its moving averages, 31% of the way from its 52-week low to high. This is a snapshot of current market data, not a forecast.
What’s behind the score
Price trendMixed vs its moving averages
52-week range31% of the way from its 52-week low to high
Market cap
$55.0M
52-wk high
1.75
52-wk low
0.39
50-day avg
0.70
200-day avg
0.85
Trailing P/E
—